In this scenario, high levels of ER stress and proteotoxicity levels requiring modulation by the CDKN2A-p53 signaling may have provided a selective advantage to tumor cells that had lost the (likely) pathogenic TP53 allele. This evidence concerns the gene CDKN2A and neoplasm.